Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of Ketorolac in Infants Undergoing Surgery
This study is currently recruiting participants.
Study NCT00014716   Information provided by FDA Office of Orphan Products Development
First Received: April 10, 2001   Last Updated: June 23, 2005   History of Changes

April 10, 2001
June 23, 2005
January 2001
 
 
 
Complete list of historical versions of study NCT00014716 on ClinicalTrials.gov Archive Site
 
 
 
Randomized Study of Ketorolac in Infants Undergoing Surgery
 

OBJECTIVES:

I. Determine the pharmacokinetics of ketorolac in infants following surgery.

II. Determine the analgesic efficacy of this drug, in terms of infant pain score, time to first opiate medication, and total opioid administration, in these patients.

III. Determine the toxicity of this drug in these patients.

PROTOCOL OUTLINE:

This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (0-7 days vs 8-30 days vs 31-90 days vs 91-180 days vs 181-365 days vs 12-18 months). Patients are randomized to one of three treatment arms.

Arm I: Patients receive low-dose ketorolac IV over 10 minutes on postoperative day 1 and morphine IV every 1-4 hours as needed. Treatment with ketorolac may continue every 8 hours for 2 days.

Arm II: Patients receive high-dose ketorolac and morphine as in arm I.

Arm III: Patients receive normal saline IV over 10 minutes on postoperative day 1 and morphine as in arm I.

Patients in all arms are assessed for pain score every 2 hours for 4 hours prior to treatment and for 12 hours after treatment.

 
Interventional
Treatment, Randomized, Double-Blind, Placebo Control
  • Pain
  • Intraoperative Complications
  • Postoperative Complications
Drug: ketorolac
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
90
 
 

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Full-term infants (at least 36 weeks gestation at birth) who are scheduled for one of the following surgeries requiring hospital admission postoperatively: exploratory laparotomy, pyloromyotomy, cleft lip repair, cleft palate repair, craniectomy, placement of ventriculo-peritoneal shunts, urologic surgery (with normal renal function), orthopedic procedures

No post-operative analgesia managed with ongoing epidural infusions; single dose caudal epidural injections given intraoperatively allowed

--Prior/Concurrent Therapy--

Biologic therapy: Not specified

Chemotherapy: Not specified

Endocrine therapy: Not specified

Radiotherapy: Not specified

Surgery: See Disease Characteristics

Other: No concurrent gastrotonic agents such as reglan or cisapride; no concurrent coumadin or therapeutic heparin

--Patient Characteristics--

Performance status: Not specified

Hematopoietic: No patient or family history of bleeding or coagulation defects

Hepatic: Hepatic function normal; no prior hepatic transplantation

Renal: Renal function normal; no prior renal transplantation

Other: No history of gastrointestinal bleeding; no closure of large gastroschisis or omphalocele defects (with increased intra-abdominal pressure); no prior repair of diaphragmatic hernia; no allergy to ketorolac

Both
up to 18 Months
No
 
United States
 
NCT00014716
 
199/15737, CHMC-S-FDR001815
FDA Office of Orphan Products Development
Seattle Children's Hospital
Study Chair: Anne M. Lynn Seattle Children's Hospital
FDA Office of Orphan Products Development
May 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP